Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 5, pp 1437–1444 | Cite as

Strategies for Managing Intraoperative Discovery of Limited Colorectal Peritoneal Metastases

  • Antoine Mariani
  • Maximiliano Gelli
  • Isabelle Sourrouille
  • Léonor Benhaim
  • Matthieu Faron
  • Charles Honoré
  • Dominique Elias
  • Diane GoéréEmail author
Peritoneal Surface Malignancy
  • 100 Downloads

Abstract

Background

Management of limited synchronous colorectal peritoneal metastases (CRPM) is critical to outcome. Resection of the primary tumor and CRPM can be performed concurrently, followed by hyperthermic intraperitoneal chemotherapy (HIPEC) either immediately, during the same procedure (one-stage), or during a systematic second-stage procedure (two-stage).

Objective

The aim of this study was to compare these two strategies for morbidity, mortality, and survival.

Methods

All patients presenting with limited (initial Peritoneal Cancer Index [PCI] ≤ 10) synchronous CRPM who had undergone complete cytoreductive surgery plus HIPEC between 2000 and 2016 were selected from a prospectively maintained institutional database.

Results

Overall, 74 patients were included—31 in the one-stage group and 43 in the two-stage group. During second-stage surgery, a peritoneal recurrence was diagnosed in 37 (86%) patients, 12 of whom had a PCI > 10 (28%) and 2 of whom had unresectable disease (5%). Among the one-stage group, peritoneal recurrence occurred in 29% of patients after a median delay of 23 months. Overall survival at 1, 3, and 5 years was similar between the two groups, i.e. 96%, 59%, and 51% for the one-stage group, and 98%, 77%, and 61% for the two-stage group. A PCI > 10 at the time of HIPEC, as well as liver metastases, were independent negative prognostic factors.

Conclusions

For incidental limited CRPM diagnosed during primary tumor resection, one-stage curative treatment is preferable, avoiding a supplementary surgical procedure. Given the critical issues associated with completeness of resection, patients should be referred to centers specialized in peritoneal surgery.

Notes

Acknowledgment

The authors thank Sarah MacKenzie, PhD, for manuscript editing.

Disclosures

Antoine Mariani, Maximiliano Gelli, Isabelle Sourrouille, Léonor Benhaim, Matthieu Faron, Charles Honoré, Dominique Elias, and Diane Goéré have no disclosures or funding sources to report.

References

  1. 1.
    Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705.CrossRefPubMedGoogle Scholar
  2. 2.
    Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.CrossRefPubMedGoogle Scholar
  3. 3.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Leung V, Huang N, Liauw W, et al. High risk features of primary colorectal carcinomas which subsequently undergo peritonectomy. Eur J Surg Oncol. 2016;42:836–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Klaver CEL, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19:224–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Quenet F, Goéré D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.CrossRefPubMedGoogle Scholar
  10. 10.
    Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.PubMedGoogle Scholar
  11. 11.
    Matsuda K, Hotta T, Takifuji K, et al. Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery. 2012;151:238–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Mulsow J, Merkel S, Agaimy A, et al. Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases. Br J Surg. 2011;98:1785–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Elias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 [abstract no. LBA3503]. J Clin Oncol. 2018;36(18 Suppl).Google Scholar
  15. 15.
    Navez J, Remue C, Leonard D, et al. Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: report from a single-centre experience. Ann Surg Oncol. 2016;23:666–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Elias D, Faron M, Iuga BS, et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. 2015;261:157–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Koh J-L, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Honoré C, Goéré D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Braam HJ, Boerma D, Wiezer MJ, et al. Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. Eur J Surg Oncol. 2013;39:988–93.CrossRefPubMedGoogle Scholar
  20. 20.
    D Goere D, Glehen O, Quenet F, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP—NTC01226394) [abstract no. 3531]. J Clin Oncol. 2018;36 (15 Suppl).Google Scholar
  21. 21.
    Machairas N, Charalampoudis P, Molmenti EP, et al. The value of staging laparoscopy in gastric cancer. Ann Gastroenterol. 2017;30:287–94.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Najah H, Lo Dico R, Grienay M, et al. Single-incision flexible endoscopy (SIFE) for detection and staging of peritoneal carcinomatosis. Surg Endosc. 2016;30:3808–15.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Antoine Mariani
    • 1
  • Maximiliano Gelli
    • 1
  • Isabelle Sourrouille
    • 1
  • Léonor Benhaim
    • 1
  • Matthieu Faron
    • 1
  • Charles Honoré
    • 1
  • Dominique Elias
    • 1
  • Diane Goéré
    • 1
    • 2
    Email author
  1. 1.Department of Visceral and Oncological SurgeryGustave RoussyVillejuif CedexFrance
  2. 2.Department of Visceral and Oncologic SurgeryHôpital Saint-Louis, APHPParisFrance

Personalised recommendations